Carboplatin

Urinary Bladder Carcinoma

G1 Therapeutics, Inc.Small moleculePhase 3Active

BB

67/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 64/ 100
Competitive Position: 73/ 100

Competitive context

120 Active assets in the Urinary Bladder Carcinoma cohort.

Asset / Sponsor	Phase	Rating
Cis-Diamminedichloroplatinum Ii G1 Therapeutics, Inc.	Phase 3	BBB
Trastuzumab NKGen Biotech, Inc.	Phase 2	BB
Cyclophosphamide Beijing Biotech	Phase 3	BB
Pembrolizumab Essen Biotech	Phase 3	BB
Vinblastine University of Southern California	Phase 3	BB

View all 50 →

Same molecule, other indications

Carboplatin is also rated in:

lung large cell carcinomaActive

A

Indicative · Phase 4

80 / 100

primary peritoneal carcinomaActive

BBB

Indicative · Phase 3

76 / 100

non-small cell squamous lung carcinomaActive

BBB

Indicative · Phase 3

76 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.